Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA)

NCT05549167 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

117

Enrollment

OTHER

Sponsor class

Conditions

Juvenile Nasopharyngeal Angiofibroma

Interventions

DRUG: Sirolimus

Sponsor

Federal Research Institute of Pediatric Hematology, Oncology and Immunology